Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06865079 · ClinicalTrials.gov registry record · Phase 2

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

A Phase 2 study of Osteoarthritis (OA) of the Knee, sponsored by OrthoTrophix.

Active
Registry status
Phase 2
Development phase
270
Enrollment target
20
Study locations

NCT06865079 is a Phase 2 study of Osteoarthritis (OA) of the Knee that is active but no longer recruiting, run by OrthoTrophix. The registered enrollment target is 270 participants, below the 1,380-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06865079, a Phase 2 study of Osteoarthritis (OA) of the Knee, is active but no longer recruiting, sponsored by OrthoTrophix.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

Interventions

  • DRUG TPX-100 200mg, Once weekly for 4 weeks
  • OTHER PBS

Study Locations (20)

California

  • Legent Orthopedic Hospital - Carrolton
  • Medvin Clinical Research - Covina
  • CORE Orthopaedic Medical Center - Encinitas
  • Marvel Clinical Research (Elite Clinical Network) - Huntington Beach
  • Medvin Clinical Research Center - Riverside
  • Medvin Clinical Research Center - Tujunga
  • Medvin Clinical Research Center - Whittier

Florida

  • K2 Medical Research - Maitland
  • Wellness Research Center - Miami
  • Well Pharma Medical Research - Miami
  • Las Mercedes Medical Research - Miami

Arizona

  • Elite Clinical Network - Scottsdale
  • Noble Clinical Research - Tucson

Kansas

  • AMR Kansas City - Kansas City
  • University of Kansas Medical Center - Kansas City

Georgia

  • Drug Studies of America - Marietta

Kentucky

  • AMR Lexington - Lexington

Louisiana

  • Accurate Clinical Research Inc. - Lake Charles

Minnesota

  • Mayo Clinic (Rochester) - Rochester

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2025-05-09
Est. Completion 2027-04-15
Phase Phase 2

Sponsor

OrthoTrophix

3 total trials

What the Registry Record Tells You About NCT06865079

The ClinicalTrials.gov registry entry for NCT06865079 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,380-participant average among 8 other Osteoarthritis (OA) of the Knee trials with a reported enrollment target (80% lower). The listed sponsor is OrthoTrophix, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis (OA) of the Knee appearing as the primary indexed condition, and to 2 interventions - of which TPX-100 200mg, Once weekly for 4 weeks is the first listed.

NCT06865079 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06865079 about?

NCT06865079 is a clinical study titled "53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee". 53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

What is the current status of trial NCT06865079?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2025-05-09. Estimated completion is 2027-04-15.

What conditions does trial NCT06865079 study?

This clinical trial studies the following conditions: Osteoarthritis (OA) of the Knee.

What interventions are being tested in trial NCT06865079?

The interventions under investigation include: TPX-100 200mg, Once weekly for 4 weeks (DRUG), PBS (OTHER).

Who is sponsoring clinical trial NCT06865079?

This trial is sponsored by OrthoTrophix, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06865079 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis (OA) of the Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.